Platelet-rich plasma, or PRP, is a regenerative treatment made from your own blood and used in selected musculoskeletal, neurological, gynecological and pulmonary conditions to support repair, modulate inflammation and improve function. At MBR Health on the Gold Coast, PRP is used for carefully selected cases of osteoarthritis, tendon injury, ligament injury, muscle injury, pulmonary issues and some nerve-related pain pathways.
But PRP is not a generic product. The quality of a PRP treatment depends on the platelet dose, the cellular composition, the way it is prepared, and whether it is delivered accurately to the tissue actually driving the problem. That is why PRP at MBR Health is selected only after diagnosis has been defined and the biological target is clear.
If you have ever had PRP that did not work, please see “Why my PRP didn’t work” and for further information please see:
Not all PRP delivers the same result. The outcome depends on what is delivered, where it is placed and whether the biology suits the tissue. Five key factors determine whether treatment is likely to work.
PRP is not simply “spun blood.” The number of platelets delivered matters, because platelets carry many of the signalling molecules that drive the biological response. Recent reviews suggest clinical outcomes in some musculoskeletal applications, particularly knee osteoarthritis, may improve when a more meaningful platelet dose is delivered rather than a very low-dose preparation.
PRP only works at the tissue it reaches. A joint surface, tendon origin, partial tear, ligament insertion, enthesis and nerve-adjacent plane are not the same target. If the biologic is not placed accurately, the treatment may underperform even when the PRP itself is good. That is why delivery should be selected according to the anatomy and performed under imaging guidance where appropriate.
You are the pharmacy for this treatment. PRP is made from your own blood, so the functional quality of your platelets matters, not just the count. Some medications — particularly non-selective NSAIDs and antiplatelet drugs — can impair platelet activation or growth factor release, which may reduce the biological quality of the final PRP product. This is one reason pre-procedure preparation matters.
How PRP is prepared can influence what is ultimately delivered. Important variables include the preparation method, centrifugation protocol, sterility pathway, anticoagulant choice, time from collection to injection, and which cellular and plasma fractions are preserved or discarded. These details can affect platelet recovery, activation behaviour and the growth factor profile of the final product. A closed, well-controlled preparation pathway helps support product quality and procedural safety.
Adjunctive strategies may sometimes be discussed to support recovery after PRP, but they should be presented carefully. Rehabilitation, load modification and tissue-specific physiotherapy remain the most established adjuncts. Hyperbaric oxygen therapy has some emerging musculoskeletal literature, but the overall evidence remains limited and protocols are not standardised. Peptide-based adjuncts are even less established for musculoskeletal PRP pathways, and in Australia many peptide products are regulated as therapeutic goods, with recent TGA warnings about unapproved peptide products and their safety. Any discussion of adjuncts should therefore be selective, evidence-aware and clinically individualised.
The information on this page is intended as general health information only and does not constitute medical advice. Platelet-rich plasma therapy at MBR Health is performed following referral from a treating GP or specialist, with suitability determined on an individual basis. All procedures carry potential risks and benefits that will be discussed prior to treatment as part of the informed consent process. Some applications of PRP listed on this page — including pulmonary applications — are investigational in nature, based on emerging case study evidence and not yet supported by established clinical guidelines for routine therapeutic use.
Patients interested in investigational applications are encouraged to discuss individual suitability with their treating clinician. MBR Health does not guarantee specific clinical outcomes from PRP therapy. Results vary depending on individual patient factors, the nature of the condition and the specific application performed.
PRP may be considered for selected joints with pain, inflammation, stiffness and early to moderate degenerative change. In appropriately selected osteoarthritis pathways, the evidence base for PRP is stronger than many patients realise.
Tendinopathy, partial tearing and insertional tendon pain affecting structures such as the Achilles, patellar tendon, elbow tendons and rotator cuff.
Selected ligament injuries and instability patterns where tissue quality, load demands and healing response matter.
Persistent or recurrent soft-tissue injury where healing has been incomplete, delayed or structurally poor.
Selected insertional and spine-adjacent pain pathways where imaging and anatomy support a biologic treatment rationale.
Selected neuropathic or entrapment-related pathways where PRP may be considered as part of a more targeted image-guided strategy.
Selected pulmonary pathways may be considered in carefully chosen cases where conventional treatment has not achieved the desired response and there is a clear biological rationale.
In selected cases, PRP may be explored where standard treatment pathways have been exhausted and the anatomy, tissue behaviour and clinical context support a regenerative approach.
US-guided PRP KNEE Injection PRP is not suitable for every patient, every tissue or every pain pattern. Suitability depends on diagnosis, imaging findings, medical history, tissue viability, alternative treatment options and the evidence available for the condition being treated.
This is one of the reasons PRP should sit inside a diagnosis-led medical pathway rather than being offered as a standalone trend treatment.
